19F MRI to Evaluate Regional Ventilation in Healthy Subjects and Subjects With Cystic Fibrosis

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

EARLY_PHASE1

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-07-01

Study Completion Date

2018-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

An open label non-randomized study enrolling up to 20 healthy participants and up to 30 participants with cystic fibrosis to establish a healthy versus disease comparison. Each participant will receive a mixture of inert gas (perfluoropropane (PFP)) in a ratio of 79% PFP to 21% oxygen as a contrast agent to enhance visualization of the airway and alveolar spaces using magnetic resonance imaging of inert gas/oxygen mixtures. The study consists of a screening visit followed by up to 2 study visits.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

19F MRI of Ventilation in Subjects With Cystic Fibrosis Undergoing Treatment for Pulmonary Exacerbation

NCT03497117

Cystic Fibrosis

TERMINATED EARLY_PHASE1

Comparison of 129Xe MRI With 19F MRI in CF Lung Disease

NCT03482960

Cystic Fibrosis

COMPLETED EARLY_PHASE1

Quantitation and Spatial Registration of Airways Dysfunction With Dynamic 19F MRI in Cystic Fibrosis

NCT06057714

Cystic Fibrosis Ventilatory Defect

RECRUITING

19F MRI in Healthy Children and Children With Mild Cystic Fibrosis Lung Disease

NCT06066723

Cystic Fibrosis in Children

RECRUITING

Regional Monitoring of CF Lung Disease

NCT06339593

Cystic Fibrosis

RECRUITING EARLY_PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The goal of this study is to evaluate the ability of conventional 'thermally' polarized perfluorinated gases (19F) mixed with oxygen to detect changes in ventilation using magnetic resonance imaging (MRI). A secondary goal is to assess the repeatability and the within-subject variability of these findings in CF lung disease. This is an open label pilot study expanding on work by other investigators currently using this technique in human subjects. Projection images using controlled breathing techniques will be obtained using 19F MRI, correlating spirometric variables with regional distribution of the gases.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Cystic Fibrosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

This study enrolls both healthy volunteers and volunteers with cystic fibrosis. Both healthy and CF participants will receive the same treatment throughout the entirety of the study.

Primary Study Purpose

OTHER

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

19F MRI with PFP

PFP gas will be administered using a full-face mask during the MRI. Images are acquired during 12-second breath-hold after every 3rd breath. Before and after the MRI is complete, participants will perform spirometry maneuvers in a room outside of the magnet.

Group Type EXPERIMENTAL

PFP

Intervention Type DRUG

* Composition: inhaled PFP, a gaseous contrast agent (79% PFP, 21% O2, pre-mixed, medical grade gas)
* Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.
* Dosage: Two controlled breaths of contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.
* Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

PFP

* Composition: inhaled PFP, a gaseous contrast agent (79% PFP, 21% O2, pre-mixed, medical grade gas)
* Administration: Full-face disposable ventilation mask and a standard Douglas Bag system.
* Dosage: Two controlled breaths of contrast gas followed by a full breath and a 12-second breath-hold and scan for image acquisition.
* Frequency: Repeated 5 times followed by an identical five cycles with room air to ensure PFP gas wash-out has occurred.

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Perfluoropropane gas (C3F8); 19F

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Non-smokers (\<10 pack-year history, and no active smoking in last 1 year);
* No evidence of prior lung disease or lung injury by medical history, physical exam, and/or spirometry testing;
* Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial.
* Participants must be willing and able to comply with scheduled visits and other trial procedures.

* Non-smokers (\<10 pack year history and no active smoking in the past year;
* Diagnosis of cystic fibrosis as via standard sweat chloride/phenotypic features/genotyping
* Stable lung disease as evidenced by no change in respiratory medications or change in FEV1 of \>15% from baseline over the preceding 4 weeks prior to enrollment
* Baseline FEV1 \>30% of predicted. Roughly equivalent numbers of CF subjects with mild FEV1 \>80% of predicted), moderate (FEV1 50-80% of predicted) and severe (FEV1 \<50% of predicted) will be targeted for enrollment.
* No use of supplemental oxygen
* Evidence of a personally signed and dated informed consent document indicating that the subject has been informed of all pertinent aspects of the trial.
* Participants must be willing and able to comply with scheduled visits and other trial procedures.

Exclusion Criteria

* Active or past smokers with less than 1 years since quitting or \>10 pack-year smoking history
* Unable to undergo a 3.0-Tesla MRI exam of the lungs and chest because of contraindications including

1. Occupation (past or present) of machiner, welder, grinder;
2. Injury to the eye involving a metallic object
3. Injury to the body by a metallic object (bullet, BB, shrapnel)
4. Presence of a cardiac pacemaker or defibrillator
5. Presence of aneurysm clips
6. Presence of carotid artery vascular clamp
7. Presence of neurostimulator
8. Presence of insulin or infusion pump
9. Presence of implanted drug infusion device that is not known to be MRI compatible (i.e., was placed outside of UNCH or is older than 10 years)
10. Bone growth or fusion simulator
11. Presence of cochlear, otologic or ear implant
12. Any type of prosthesis (eye, penile, etc.)
13. Artificial limb or joint
14. Non-removable electrodes (on body, head or brain)
15. Intravascular stents, filters or coils
16. Shunt (spinal or intraventricular)
17. Swan-ganz catheter
18. Any implant held in place by a magnet
19. Transdermal delivery system (e.g. Nitro)
20. IUD or diaphragm
21. Tattooed makeup (eyeliner, lips, etc.) or tattoos covering \>25% of body surface area
22. Body piercings (MUST BE REMOVED BEFORE MRI)
23. Any metal fragments
24. Internal pacing wires
25. Metal or wire mesh implants
26. Hearing aid (REMOVE BEFORE MRI) aa. Dentures (REMOVE BEFORE MRI) bb. Claustrophobia
* Unable to tolerate inhalation of gas mixture
* Participation in a clinical trial with a study drug that may impact lung function in the past 14 days
* Other severe acute or chronic medical or psychiatric condition or clinical laboratory abnormality that may increase the risk associated with trial participation or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the participant inappropriate for entry into this trial.
* Pregnancy: women of childbearing potential must have a confirmed negative urine pregnancy test on the day of the MR scan, prior to the MRI scan.

* Active or past smokers with less than 1 years since quitting or \>10 pack-year smoking history
* Active asthma flare, as perceived by the study physician or unstable asthma characterized by advancement of asthma therapy in the last month or two courses of oral steroids in the past six months.
* Unable to undergo a 3.0-Tesla MRI exam of the lungs and chest because of contraindications including

1. Occupation (past or present) of machiner, welder, grinder;
2. Injury to the eye involving a metallic object
3. Injury to the body by a metallic object (bullet, BB, shrapnel)
4. Presence of a cardiac pacemaker or defibrillator
5. Presence of aneurysm clips
6. Presence of carotid artery vascular clamp
7. Presence of neurostimulator
8. Presence of insulin or infusion pump
9. Presence of implanted drug infusion device that is not known to be MRI compatible (i.e., was placed outside of UNCH or is older than 10 years)
10. Bone growth or fusion simulator
11. Presence of cochlear, otologic or ear implant
12. Any type of prosthesis (eye, penile, etc.)
13. Artificial limb or joint
14. Non-removable electrodes (on body, head or brain)
15. Intravascular stents, filters or coils
16. Shunt (spinal or intraventricular)
17. Swan-ganz catheter
18. Any implant held in place by a magnet
19. Transdermal delivery system (e.g. Nitro)
20. IUD or diaphragm
21. Tattooed makeup (eyeliner, lips, etc.) or tattoos covering \>25% of body surface area
22. Body piercings (MUST BE REMOVED BEFORE MRI)
23. Any metal fragments
24. Internal pacing wires
25. Metal or wire mesh implants
26. Hearing aid (REMOVE BEFORE MRI) aa. Dentures (REMOVE BEFORE MRI) bb. Claustrophobia
* Unable to tolerate inhalation of gas mixture
* Participation in a clinical trial with a study drug that may impact lung function in the past 14 days
* Other severe acute or chronic medical or psychiatric condition or laboratory abnormality that may increase the risk associated with trial participation or may interfere with the interpretation of trial results and, in the judgment of the investigator, would make the participant inappropriate for entry into this trial.
* Pregnancy; women of childbearing potential must have a confirmed negative urine pregnancy test on the day of the MR scan, prior to the MRI scan.

Minimum Eligible Age

18 Years

Maximum Eligible Age

99 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes